Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster.
The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website.
By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.
The European Commission on Friday approved the first monoclonal antibody to prevent respiratory syncytial virus (RSV) among all infants and newborns, amid a rise of cases of the highly contagious virus, which can pose a danger to infants and older adults.
KEY FACTS
The European Commission approved Beyfortus, an injection manufactured by AstraZeneca and Sanofi to be given to infants from birth through their first RSV season—which typically begins in late fall—to protect against the virus, which is the most common cause of lower respiratory tract infections like bronchiolitis and pneumonia in infants.
It’s the first regulatory body to approve the injection, basing its decision on clinical trial results, which showed Beyfortus was safe compared to a placebo and reduced the incidence of lower respiratory tract infections caused by RSV by 74.5%, according to the pharmaceutical companies.
The approval marks a “significant achievement for the scientific community” to address a “persistent, global unmet need in RSV prevention, Iskra Reic, the executive vice president of vaccines and immune therapies at AstraZeneca, said in a statement.
Children’s hospitals call on Biden to declare emergency in response to ‘unprecedented’ RSV surge
PUBLISHED FRI, NOV 18 20228:52 AM EST
UPDATED FRI, NOV 18 20226:30 PM EST
The Children’s Hospital Association and the American Academy of Pediatrics told the Biden administration that “unprecedented levels” of RSV combined with increasing flu circulation are pushing some hospitals to the breaking point.
They asked the federal government to declare an emergency to provide hospitals with added flexibility to meet the surge.
Infants 6 months and younger are getting hospitalized with RSV at seven times the rate observed before the Covid-19 pandemic in 2018, according to CDC data.
